Work

Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx370.027

Authors: M. Eisenberger, A-C. Hardy-Bessard, C.S. Kim, L. Géczi, D. Ford, L. Mourey, J. Carles, P. Parente, A. Font, G. Kacsó, G. Barnes, H. Wang, W. Zhang, A. Ozatilgan, J. de Bono

Institutions: Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Asan Medical Center, National Institute of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham City Hospital, Institut Claudius Regaud, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Monash University, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Iuliu Hațieganu University of Medicine and Pharmacy, Sanofi (United States), Royal Marsden NHS Foundation Trust

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, Sanofi, Astellas Pharma, Genentech

OpenAlex ID: W2762122166

FWCI:

Cites:

Cited by:

Related to: 10